Anuh Pharma Ltd

Anuh Pharma Promoter Reclassification

Anuh Pharma's promoter group member Nina Vijay Shah withdrew her request to reclassify to the public category. She remains in the promoter group.

Anuh Pharma Q2 FY27 Results: Net Profit ₹11.2 Cr, Up 47.4% YoY

Anuh Pharma Ltd reported revenue from operations of ₹185.2 Cr (-0.4% YoY) and net profit of ₹11.2 Cr (+47.4% YoY) for Q2 FY27.

Key figure

Net profit ₹11.2 Cr · +47.4% YoY

Anuh Pharma Board Meeting Date

Anuh Pharma's board meets on 30 October 2026 to approve Q1/H1 FY27 results. Trading window closed for insiders until 1 November 2026.

Anuh Pharma Acquisition Worth ₹72.9 Cr

Anuh Pharma signed an Asset Transfer Agreement to acquire a manufacturing facility from Vanquest Pharma for ₹72.90 Crore, increasing its production capacity by 525 MTPA.

Value

₹72.90 Cr

manufacturing capacity

525.0 MTPA

Anuh Pharma Debt & Borrowing: ₹75 Cr

Anuh Pharma Ltd board approved a loan of ₹75 Crore to finance manufacturing asset investments for expanding production capacity.

Value

₹75.00 Cr

Anuh Pharma Other Announcement

Anuh Pharma Ltd filed the quarterly compliance certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018, as issued by its RTA.

Anuh Pharma Legal & Regulatory

Anuh Pharma disclosed a Rs. 9,93,206 tax demand under Section 156, Income Tax Act, for AY 2018-19. The company plans to appeal before the CIT.

Value

₹0.10 Cr

Anuh Pharma Investor Presentation: Key Takeaways

Anuh Pharma reported strong Q1 FY27 results with 4% YoY revenue growth and 38% PAT growth, driven by a shift to high-value regulated markets.

Call

Guides 18% growth

Anuh Pharma Management Change

Anuh Pharma announced the re-appointment of directors Arun Lalchand Todarwal and Bipin N. Shah, and the appointment of Ankit Kishor Chande as Cost Auditor.

Anuh Pharma Annual General Meeting

Anuh Pharma Ltd held its 66th Annual General Meeting on August 12, 2026. The meeting covered the adoption of financial statements, dividend declaration, and director appointments.